Autism Spectrum Disorders affect one in 68 children. And when your child is that one, you embark on a quest to do whatever it takes to reverse autism’s effects. At Hope Network’s Center for Autism, your child goes from being a number to becoming our utmost concern. And we’ll stop at nothing to help the healing begin.
Center for Autism clinically utilizes outcome measures that have been validated in research.
We lead the conversation of outcome measurement in autism early interventions by using these in a more sophisticated manner than our competitors and giving parents and other stakeholders an unprecedented lens into the development of autistic children and their response to applied behavior analysis (ABA).
Our outcome measurement process gets under way the moment we begin to evaluate your child.
We not only use evidence-based, validated tools such as the Autism Diagnostic Observation Schedule, the Vineland Adaptive Behavior Scale, Wechsler intelligence tests, and the Verbal Behavior Milestones Assessment and Placement Program (VB-MAPP), but we use them systematically and we track children over time.
Starting with the first day of therapy, we also integrate cloud-based, real-time data collection using the Catalyst system by DataFinch. This system provides us overall with three independent levels of outcome measures – daily measures of skills mastered and behavior frequencies and durations, independent biannual measurement of verbal behavior milestones, and further independent annual measurement of high level outcomes such as IQ gains and academic mainstreaming.
We have established a baseline in all of these areas.
Based on a large sample of approximately 75 children who received ABA from us in 2015, we have established an 80% window of ABA response, as measured by the VB-MAPP, so that we can now identify children who consistently respond poorly to therapy (in order to intensify alternative/complementary recommendations), as well as the top responders at our Center, who can be used as case studies to further improve therapy.
We have established our therapy against large-scale clinical trials, using the same outcome measures, and demonstrating that approximately 30% of children in our ABA program have an IQ gain of at least one standard deviation, one year into therapy with us, and that more than 50% do two years into therapy with us.